🔎 Trials Near Me

Akèy › Limfòm Burkitt › Tennessee

Etid klinik pou Limfòm Burkitt nan Tennessee

10 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Tennessee.

Vil nan Tennessee

Tèks ofisyèl etid la (Anglè)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • East Tennessee Childrens Hospital, Knoxville
  • The Children's Hospital at TriStar Centennial, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • The Children's Hospital at TriStar Centennial, Nashville
  • ak 1 plis
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • East Tennessee Childrens Hospital, Knoxville
  • The Children's Hospital at TriStar Centennial, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • T C Thompson Children's Hospital, Chattanooga
  • East Tennessee Childrens Hospital, Knoxville
  • The Children's Hospital at TriStar Centennial, Nashville
  • ak 1 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Franklin
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT07109219

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

  • St. Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT06777979

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

  • St. Jude Children's Research Hospital, Memphis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 29, 2026 · NCT07048535

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • Sarah Cannon - HCA Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 15 a 50 · Tout sèks · Mizajou Sep 9, 2025 · NCT04150497

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • TriStar Bone Marrow Transplant, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.